A Phase 1, Randomized, Placebo-controlled, Double Blind, Single, Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ANX005 Monotherapy and ANX005 in Combination With IVIg in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2018
At a glance
- Drugs ANX 005 (Primary)
- Indications Autoimmune disorders; CNS disorders
- Focus Adverse reactions
- Sponsors Annexon
- 29 Jan 2018 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 29 Jan 2018 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 03 Jan 2017 Status changed from planning to recruiting.